晚期肺肉瘤样癌的异质性及其对免疫检查点抑制剂的疗效
这项多中心研究纳入2018年8月至2022年5月中国11个中心的113例晚期肺肉瘤样癌(PSC)患者,评估免疫检查点抑制剂(ICI)的疗效及机制。接受ICI治疗的患者中位无进展生存期(PFS)为8.77个月(95%CI 4.21–13.32),ICI联合抗血管生成药物可显著延长PFS(p=0.04)。肝转移和联合抗血管生成治疗分别是PFS的独立危险因素(HR=3.652,p=0.019)和保护因素(HR=0.435,p=0.017)。
要点
- 晚期PSC接受ICI治疗的中位PFS为8.77个月(95%CI 4.21–13.32)。
- ICI联合抗血管生成药物较单用ICI显著延长PFS(p=0.04)。
- 肝转移为PFS独立危险因素(HR=3.652),联合抗血管生成治疗为独立保护因素(HR=0.435)。
核心结论
- ICI对晚期PSC显示出有希望的获益,联合抗血管生成治疗可能是更有效的治疗策略。
研究设计与样本
- 多中心研究,纳入2018年8月至2022年5月中国11个中心的113例晚期PSC患者,收集临床特征与治疗信息,并对治疗前样本进行全外显子测序(WES)和全转录组测序以探索机制。
主要发现
- 接受ICI治疗的患者中位PFS为8.77个月(95%CI 4.21–13.32)。
- ICI联合抗血管生成药物较未联合者显著延长PFS(p=0.04)。
- 肝转移是PFS的独立危险因素(HR=3.652,p=0.019),联合抗血管生成药物是PFS的独立保护因素(HR=0.435,p=0.017)。
- WES显示PSC的肿瘤突变负荷(TMB)为每百万碱基对6.3个突变。
- TNFα信号通路和糖酵解相关基因高表达与更好的预后相关。
关键数值与推荐
- 接受ICI治疗患者的中位PFS为8.77个月(95%CI 4.21–13.32)。
- ICI联合抗血管生成药物较未联合者PFS显著延长(p=0.04)。
- 肝转移对PFS的HR=3.652(p=0.019),联合抗血管生成药物对PFS的HR=0.435(p=0.017)。
- PSC的TMB为每百万碱基对6.3个突变。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) have improved the prognosis of patients with non-small cell lung cancer but rarely been explored in pulmonary sarcomatoid carcinoma (PSC). This multicenter study aimed to evaluate the effectiveness of ICIs for PSC and its underlying mechanism. METHODS: Advanced PSC who received ICIs between August 2018 and May 2022 from 11 centers in China were included. Clinical characteristics and treatment information were collected. Whole-exome sequencing (WES) and whole transcriptome sequencing were conducted on pre-treatment samples to explore the mechanism. RESULTS: 113 patients with PSC were enrolled, the median PFS for patients receiving ICIs therapy was 8.77 months (95 % confidence interval, 4.21 to 13.32). Combining ICIs with anti-angiogenic agents significantly increased PFS (p = 0.04). Liver metastasis and combination therapy with anti-angiogenic agents were independent risk factors for PFS (Hazard Ratio [HR] = 3.652, p = 0.019 and HR = 0.435, p = 0.017, respectively). WES showed that PSC presented with a TMB of 6.3 mutations per million base pairs. High expression of TNFα signaling and glycolysis related gene showed a better prognosis. CONCLUSIONS: ICIs showed promising benefits for advanced PSC, and the addition of anti-angiogenic therapy might be a more effective treatment strategy for this disease.
引用
- Xie M, Chu T, Dong X, et al. Heterogeneity in advanced pulmonary sarcomatoid carcinoma and its efficacy to immune checkpoint inhibitors. Eur J Cancer. 2024. PMID: 39111208. doi:10.1016/j.ejca.2024.114260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。